Sugi Predict

Sugi Predict / Compounds / SCHEMBL4067528

SCHEMBL4067528

SCHEMBL4067528

NC(Cc1cccc(F)c1)C(O)CC(C(=O)NO)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC1A1 P43005 2/20 0.40
▸ DPP4 P27487 3/20 0.40
▸ DPP8 Q6V1X1 2/20 0.40
▸ DPP9 Q86TI2 2/20 0.40
▸ DPP7 Q9UHL4 2/20 0.40
▸ ANPEP P15144 1/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CCR1 P32246 2/20 0.38
▸ MMP1 P03956 1/20 0.38
▸ FCER2 P06734 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4069433 0.84 EPHX1 (0.40) DPP4DPP8DPP9DPP7SMN1; SMN2
SCHEMBL4069111 0.81 C3AR1 (0.45) CCR1
SCHEMBL4068352 0.81 C3AR1 (0.40) DPP4DPP8DPP9NPC1RAB9A
SCHEMBL4067524 0.80 NPC1 (0.40) ANPEPNPC1RAB9AMEN1GAA
SCHEMBL4064301 0.78 CCR1 (0.46) DPP4ANPEPCCR1
SCHEMBL4069503 0.77 CCR1 (0.48) SLC1A1DPP4DPP8DPP9DPP7
SCHEMBL5930101 0.77 NPC1 (0.41) SLC1A1DPP4DPP8DPP9DPP7
SCHEMBL3837106 0.77 CCR1 (0.60) ANPEPCCR1MMP1FCER2
SCHEMBL4069333 0.77 CCR1 (0.47) DPP4DPP8DPP9DPP7CCR1
SCHEMBL4072923 0.76 CCR1 (0.50) DPP4DPP8DPP9DPP7ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0966443-B1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER (US) 2009-01-28 — — EP disclosed
US-20020198207-A1 Novel Hexanoic acid derivatives KATH JOHN CHARLES (US) 2002-12-26 — — US disclosed
US-6403587-B1 AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND PFIZER INC. 2002-06-11 — — US disclosed
EP-0966443-A1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER INC. (US) 1999-12-29 — — EP disclosed
WO-1998038167-A1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER INC. (US) 1998-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198207-A1 Novel Hexanoic acid derivatives HCAR3, HCAR1, FFAR1 SLC1A1 1741/4885DPP4 1477/4885DPP8 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.